Shom Goel, MD | Authors


POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer

November 16, 2015

We acknowledge that the “more is better” approach may not always hold true. For example, preclinical data provided a rationale for combining pertuzumab with T-DM1, but recent reports suggest that this strategy may not prove more effective than single-agent T-DM1 therapy in the clinic.